Tags

Type your tag names separated by a space and hit enter

Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):584-93.CC

Abstract

PURPOSE

The vascular endothelial growth factor (VEGF) family plays a critical role in tumor angiogenesis and lymphangiogenesis. We characterized, at the mRNA and protein levels, the expression of VEGF-A and VEGF-D and their cognate receptors, VEGFR-1, VEGFR-2, and VEGFR-3 in early- and advanced-stage prostate cancer specimens.

EXPERIMENTAL DESIGN

The levels of VEGF-A and VEGF-D mRNA in early- and advanced-stage specimens were compared using an angiogenic gene array and were confirmed by quantitative real-time PCR. Receptor protein levels and activation status were determined by immunoblotting. Spatial expression of the proteins was evaluated using immunohistochemistry with fresh and archival tissues from benign prostatic hypertrophy specimens, early-stage prostate specimens, and advanced-stage metastatic specimens. Circulating plasma levels of these growth factors were measured using ELISAs.

RESULTS

We observed that expression patterns of VEGF isotypes corresponded to the prostate cancer stage: high expression of angiogenic growth factor VEGF-A was observed in early-stage prostate specimens, whereas high expression of lymphangiogenic growth factor VEGF-D was associated with advanced-stage metastatic disease. All VEGF receptors were present at variable levels in all specimens, but their activation states varied in a stage-specific manner. VEGFR-1 and, to a limited extent, VEGFR-2 were activated in early-stage specimens, whereas VEGFR-2 and VEGFR-3 were activated in advanced-stage specimens.

CONCLUSIONS

Our results suggest that lymphangiogenic markers, such as VEGF-D and VEGFR-2 and VEGFR-3, may be better than angiogenic markers as targets of therapeutic intervention in advanced-stage prostate disease.

Authors+Show Affiliations

Department of Internal Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA. Kaushalvarsha@uams.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15701844

Citation

Kaushal, Varsha, et al. "Stage-specific Characterization of the Vascular Endothelial Growth Factor Axis in Prostate Cancer: Expression of Lymphangiogenic Markers Is Associated With Advanced-stage Disease." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 11, no. 2 Pt 1, 2005, pp. 584-93.
Kaushal V, Mukunyadzi P, Dennis RA, et al. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res. 2005;11(2 Pt 1):584-93.
Kaushal, V., Mukunyadzi, P., Dennis, R. A., Siegel, E. R., Johnson, D. E., & Kohli, M. (2005). Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 11(2 Pt 1), 584-93.
Kaushal V, et al. Stage-specific Characterization of the Vascular Endothelial Growth Factor Axis in Prostate Cancer: Expression of Lymphangiogenic Markers Is Associated With Advanced-stage Disease. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93. PubMed PMID: 15701844.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. AU - Kaushal,Varsha, AU - Mukunyadzi,Perkins, AU - Dennis,Richard A, AU - Siegel,Eric R, AU - Johnson,Donald E, AU - Kohli,Manish, PY - 2005/2/11/pubmed PY - 2005/5/13/medline PY - 2005/2/11/entrez SP - 584 EP - 93 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 11 IS - 2 Pt 1 N2 - PURPOSE: The vascular endothelial growth factor (VEGF) family plays a critical role in tumor angiogenesis and lymphangiogenesis. We characterized, at the mRNA and protein levels, the expression of VEGF-A and VEGF-D and their cognate receptors, VEGFR-1, VEGFR-2, and VEGFR-3 in early- and advanced-stage prostate cancer specimens. EXPERIMENTAL DESIGN: The levels of VEGF-A and VEGF-D mRNA in early- and advanced-stage specimens were compared using an angiogenic gene array and were confirmed by quantitative real-time PCR. Receptor protein levels and activation status were determined by immunoblotting. Spatial expression of the proteins was evaluated using immunohistochemistry with fresh and archival tissues from benign prostatic hypertrophy specimens, early-stage prostate specimens, and advanced-stage metastatic specimens. Circulating plasma levels of these growth factors were measured using ELISAs. RESULTS: We observed that expression patterns of VEGF isotypes corresponded to the prostate cancer stage: high expression of angiogenic growth factor VEGF-A was observed in early-stage prostate specimens, whereas high expression of lymphangiogenic growth factor VEGF-D was associated with advanced-stage metastatic disease. All VEGF receptors were present at variable levels in all specimens, but their activation states varied in a stage-specific manner. VEGFR-1 and, to a limited extent, VEGFR-2 were activated in early-stage specimens, whereas VEGFR-2 and VEGFR-3 were activated in advanced-stage specimens. CONCLUSIONS: Our results suggest that lymphangiogenic markers, such as VEGF-D and VEGFR-2 and VEGFR-3, may be better than angiogenic markers as targets of therapeutic intervention in advanced-stage prostate disease. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/15701844/Stage_specific_characterization_of_the_vascular_endothelial_growth_factor_axis_in_prostate_cancer:_expression_of_lymphangiogenic_markers_is_associated_with_advanced_stage_disease_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15701844 DB - PRIME DP - Unbound Medicine ER -